Sherko Küemmel

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Xavier Pivot, Joseph Gligorov, Volkmar Müller et al. · Annals of Oncology · 2014 · 176 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 172 citations

Medicine, Oncology, Pharmacology +17

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Nadia Harbeck, Oleg Gluz, Matthias Christgen et al. · Journal of Clinical Oncology · 2017 · 150 citations

Medicine, Oncology, Pharmacotherapy +17

Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.

Gϋnter von Minckwitz, M. Kaufmann, Sherko Küemmel et al. · Journal of Clinical Oncology · 2011 · 53 citations

Medicine, Oncology, Breast Oncology +16

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.

Lajos Pusztai, Carsten Denkert, Joyce O’Shaughnessy et al. · Journal of Clinical Oncology · 2022 · 51 citations

Medicine, Oncology, Cancer Drug Toxicity Management +15